Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | C1R | P00736 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28739907 | 0.83 | SMN1; SMN2 (0.57) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4789854 | 0.79 | PDE10A (0.45) | HPGDLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3085385 | 0.77 | CYP1A2 (0.58) | HPGDLMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL396614 | 0.75 | HPGD (0.64) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL266444 | 0.75 | LMNA (0.64) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29877118 | 0.75 | LMNA (0.64) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL28010962 | 0.75 | LMNA (0.64) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30065410 | 0.75 | HPGD (0.64) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3065369 | 0.74 | LMNA (0.62) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2539705 | 0.74 | HPGD (0.62) | ALOX15HPGDLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | claimed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | claimed |
| EP-0827507-B1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM CA LTD (CA) | 1999-06-16 | — | — | EP | claimed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | claimed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | claimed |
| US-5545640-A | VIRICIDES, HIV; AIDS | BIO-MEGA/BOEHRINGER INGELEHEIM RESEARCH INC. (CA) | 1996-08-13 | — | — | US | claimed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| EP-0758021-B1 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA SPA (IT) | 2006-03-29 | — | — | EP | disclosed |
| US-6562964-B1 | Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders | PFIZER INC | 2003-05-13 | — | — | US | disclosed |
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| EP-0827507-B1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM CA LTD (CA) | 1999-06-16 | — | — | EP | disclosed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | disclosed |
| EP-0758021-A2 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA S.p.A. (IT) | 1997-02-12 | — | — | EP | disclosed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | disclosed |
| US-5545640-A | VIRICIDES, HIV; AIDS | BIO-MEGA/BOEHRINGER INGELEHEIM RESEARCH INC. (CA) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | ALOX15 2590/4885HPGD 2504/4885LMNA 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.